Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | GSPT1 | P15170 | 10/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 9/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360673 | 1.00 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL21335035 | 0.95 | CRBN (0.91) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL21335027 | 0.95 | CRBN (0.91) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240145 | 0.93 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1403564 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413700 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413473 | 0.92 | CRBN (0.85) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL68157 | 0.92 | CRBN (0.85) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL19808761 | 0.92 | CRBN (0.84) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| Hydrochloric Acid SCHEMBL62087 | 0.91 | CRBN (0.84) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2023-08-22 | — | — | US | claimed |
| US-20180267043-A1 | USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT | CELGENE CORP (US) | 2018-09-20 | — | — | US | claimed |
| EP-3204008-A1 | USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT | Celgene Corporation (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057503-A1 | USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT | CELGENE CORPORATION (US) | 2016-04-14 | — | — | WO | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240389562-A1 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | CELGENE CORPORATION (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024192146-A2 | COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | SOUTHERN RESEARCH INSTITUTE (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118251383-A | Macrocyclic compounds as proteasome beta subunit type 5 inhibitors | 利德探索中心有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024123853-A1 | TERNARY COMPLEX MODELLING FOR MOLECULAR GLUES | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| WO-2008027542-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240389562-A1 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | CRBN, CHN2, CRKL | CRBN 1/4885GSPT1 1688/4885DDB1 1308/4885 |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
| US-20180267043-A1 | USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT | TSG101, MKI67, BRCA1 | CRBN 3434/4885GSPT1 517/4885DDB1 147/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | CRBN 916/4885GSPT1 32/4885DDB1 724/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885GSPT1 1959/4885DDB1 3649/4885 |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885GSPT1 1479/4885DDB1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.